TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01263275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (Eldith DC-Stimulator (CE certified))
Description: Each tDCS session lasting continuously for 20 minutes at 2 mA
Study: NCT02177058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INTERACT Quality improvement program
Description: INTERACT training and implementation between APR 2013 and MAR 2014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quarterly surveys/data reporting
Description: The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
Study: NCT02656615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
Study: NCT02551926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual community
Study: NCT01864525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octanoic acid
Study: NCT02551926

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: brochures

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mobile phone
Study: NCT01124916

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic assisted laparoscopic abdominal sacrocolpopexy
Description: Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic abdominal sacrocolpopexy
Description: Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
Study: NCT02010021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
Study: NCT02361983

Intervention type: DEVICE
Intervention: DLT versus bronchial blockers
Description: Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
Study: NCT00765921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
Study: NCT01864525

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive capsule
Study: NCT06312501

Intervention type: DEVICE
Intervention: Satelia®Cardio
Description: Use of a remote patient monitoring system by NP Medical.

Intervention type: OTHER
Intervention: Conventional care
Description: No use of RPM solutions for follow-up
Study: NCT01714414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZD
Study: NCT03591744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study: NCT03461315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional assistance model
Description: Preventive home visits carried out by a Team Dedicated Exclusively to the Home Patient.
Study: NCT02020785

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher phosphorus period
Description: Commercially-available unaltered food/beverage products containing phosphorus additives (\~1gm/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lower phosphorus period
Description: Commercially-available unaltered food/beverage products without phosphorus additives (\<10mg/d of phosphorus) will be given for 3 weeks.~All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of \~1gm/d by receiving education on avoiding phosphorus-based additives.
Study: NCT01077531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Otelixizumab
Description: Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Matching placebo for intravenous infusion
Study: NCT00294632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Starting Dose 10 mg By Mouth Daily on Days 1-21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 By Vein Weekly for 4 Weeks
Study: NCT03208283

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Water method group
Description: During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Air insufflation group
Description: During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
Study: NCT00344305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine live, intranasal
Description: A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine live, intranasal
Description: A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.
Study: NCT02747251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthen your Shoulder
Description: A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder.
Study: NCT04264663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furazolidone
Description: Furazolidone-tetracycline-containing quadruple regimens

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinidazole
Description: tinidazole-tetracycline-containing quadruple regimens
Study: NCT02036827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
Study: NCT03358342

Intervention type: OTHER
Intervention: ePneumonia CDS
Description: ePneumonia clinical decision support system for community-onset pneumonia
Study: NCT03732729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: massage chair
Description: Patient should use massage chair, twice per day, for 30minutes
Study: NCT02554825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Futures
Description: Healthy Futures is an age-appropriate program that targets change at different social ecological levels-individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
Study: NCT03232749

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intraarticular corticosteroid injections (IACSI)
Description: ultrasound-guided IACSI will be administered

Intervention type: DRUG
Group type: OTHER
Intervention: corticosteroid injections
Description: Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Description: ultrasound-guided IACSI
Study: NCT03654092

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention.
Study: NCT03429374

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liquiband Fix8
Description: LiquiBand® Fix 8™ (Advanced Medical Solutions - Plymouth, UK) is a hernia mesh fixation device providing strong and secure mesh fixation without causing any tissue damage or mechanical trauma. This device is designed to offer precise and controlled delivery of tissue glue (n-butyl-2-cyanoacrylate), resulting in a strong mesh fixation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Absorbable tack
Description: Absorbable tack
Study: NCT03362528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4NR
Description: Investigational Medical Device collecting spectral raman data from tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WM3.4NR
Description: Investigational Medical Device collecting spectral raman data from tissue.
Study: NCT00782275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Study: NCT03386669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18
Description: Totally 60 subjects age 20-80 including 20 subjects with a diagnosis of PD,PSP,and CBS. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
Study: NCT04120714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: active D.C. transcranial stimulation (delivers a low current (1 to 2 mA)) for 10 to 30 minutes, during 5 sessions

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tDCS
Description: inactive DC transcranial stimulation (delivering a non-significant current at the beginning and end of the stimulation, simulating active stimulation) for 10 to 30 minutes, during 5 sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: * visual analogue scale (VAS)~* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~* Go-No go test~* HAM-D scale~* SF-12 quality of life scale

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: * visual analogue scale (VAS)~* impulsivity scale: Barratt Impulsiveness Scale - version 11 (BIS-11)~* Decision-making scales: Iowa Gambling Task (IGT) and Balloon Analogue Risk Task (BART)~* Go-No go test~* HAM-D scale~* SF-12 quality of life scale
Study: NCT01632683

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC
Description: C-MAC arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: Glidescope arm
Study: NCT02353299

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Silenor 6 mg
Description: Silenor 6 mg single nighttime dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Silenor 6 mg
Description: Silenor 6 mg single nighttime dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silenor 6 mg
Description: Silenor 6 mg single nighttime dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silenor 6 mg
Description: Silenor 6 mg single nighttime dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zolpidem 10 mg
Description: Zolpidem 10 mg single nighttime dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zolpidem 10 mg
Description: Zolpidem 10 mg single nighttime dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolpidem 10 mg
Description: Zolpidem 10 mg single nighttime dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zolpidem 10 mg
Description: Zolpidem 10 mg single nighttime dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-1.5 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-1.5 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-1.5 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-1.5 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-4 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-4 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo single nighttime dose-4 hours
Study: NCT00216125

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Cisplatin 50 mg/m2 day 1, 8, 29, 36
Study: NCT00985218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART System
Description: microfluidic embryo culture system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Culture dish
Description: Standard IVF culture dish
Study: NCT02353793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReadyHeat® blanket
Description: Using ReadyHeat® blanket for patient warming

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cotton wool blanket
Description: Using cotton wool blanket for patient warming
Study: NCT02324491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440 for Injectable Suspension
Description: Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440 for Injectable Suspension
Description: Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 Placebo for Injectable Suspension
Description: Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
Study: NCT04442555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HVMN Ketone Ester
Description: Commercially available ketone supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Commercially available maltodextrin supplement
Study: NCT02639702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Switching from twice-daily to once-daily clozapine dosing regimen
Study: NCT02206529

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Network Engagement+Std Treatment

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Treatment
Description: Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
Study: NCT05016492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visual-perceptual interactive game system
Description: Subjects received 30-min interactive digital game training session per week. The game system contain 7 skills training, each of which was named according to the corresponding TVPS-3.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard rehabilitation
Description: Subjects received the standard 4-week course of rehabilitation delivered in one 30-min session per week. The course of rehabilitation included: sensory integration therapy, cognitive function training and visual perception/auditory attention training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard rehabilitation
Description: Subjects received the standard 4-week course of rehabilitation delivered in one 30-min session per week. The course of rehabilitation included: sensory integration therapy, cognitive function training and visual perception/auditory attention training.
Study: NCT02706457

Intervention type: OTHER
Intervention: Barthel index for functionality
Description: The Barthel Index for functionality is done standard in all patients after intensive care admission
Study: NCT00221793

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Brain Stimulation of the Subthalamic Nucleus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Brain Stimulation of the Subthalamic Nucleus
Study: NCT00829439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa (4:1)
Description: Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
Study: NCT04071392

Intervention type: PROCEDURE
Intervention: Hysterosalpingogram (HSG)
Description: An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.

Intervention type: PROCEDURE
Intervention: Hysterosalpingogram (HSG)
Description: An infusion pump delivered saline via balloon catheter under continuous pressure monitoring. After one minute, investigators withdraw the fluid and recorded volumes in and out. Subjects then undergo hysterosalpingogram (HSG) for evaluation of tubal patency.